CBAY Live signals | Maximize Profits with Getagraph.com

BUY 91 min ago

@ $20.52

Issued: 4 Dec 2023 @ 15:25

Return: -0.78%

Previous signal: Dec 4 - 11:20

Previous signal: Sell

Return: 0.98 %

Live Chart Being Loaded With Signals

Commentary (4 Dec 2023 @ 16:00):

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases...

Stats
Today's Volume	2.62M
Average Volume	2.31M
Market Cap	2.31B
EPS	$0 ( 2023-11-13 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-21.89
ATR14	$1.199 (5.89%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-17	Mcwherter Charles	Buy	11 342	Common Stock
2023-11-17	Mcwherter Charles	Sell	11 342	Common Stock
2023-11-17	Mcwherter Charles	Sell	6 506	Employee Stock Option (right to buy)
2023-11-17	Mcwherter Charles	Sell	3 892	Employee Stock Option (right to buy)
2023-11-17	Mcwherter Charles	Sell	708	Employee Stock Option (right to buy)

INSIDER POWER
11.65
Last 100 transactions
Buy: 976 732 \| Sell: 762 577

Volume Correlation

Long: -0.74 (moderate negative)

Short: -0.71 (moderate negative)

Signal:(26) Neutral

Cymabay Therapeutics Inc Correlation

10 Most Positive Correlations
XPDB	0.96
ROCL	0.956
HWEL	0.955
IXAQ	0.953
GDNR	0.953
ARTEU	0.952
VMGA	0.952
FNVT	0.952
AVAC	0.951
PWUP	0.951

10 Most Negative Correlations
RMRM	-0.983
ASPS	-0.952
BFC	-0.945
EVLO	-0.943
CLFD	-0.942
CREG	-0.941
YJ	-0.941
STAB	-0.941
SYBT	-0.939
MMAT	-0.936

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cymabay Therapeutics Inc Correlation - Currency/Commodity

-0.12
( neutral )

-0.06
( neutral )

0.00
( neutral )

0.11
( neutral )

0.00
( neutral )

0.04
( neutral )

Cymabay Therapeutics Inc Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.350

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.320

Q2	2023
Revenue:	$31.02M
Gross Profit:	$31.02M (100.00 %)
EPS:	$-0.0079

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.360

Cymabay Therapeutics Inc

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.